Related Experiment Video
Updated: Aug 2, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Vincristine and oral etoposide in refractory multiple myeloma
R K Ganjoo1, A Williams, J S Malpas
1Imperial Cancer Research Fund, Department of Medical Oncology, St. Bartholomew's Hospital, London, UK.
Abstract:
A total of 15 patients with refractory multiple myeloma (MM; 4 primary unresponsive and 11 relapsed and resistant to re-induction/salvage therapy) received i.v. vincristine on day 1 and oral etoposide daily for 4 days, the treatment being repeated at 3-weekly intervals. The patients were re-assessed after three cycles of chemotherapy, and non-responders received no further therapy. There was no complete or partial response. A minimal response was seen in two patients, and two others showed stable disease. None of the responses was sustained, and all patients eventually had progressive disease. It is concluded that combination chemotherapy with vincristine and oral etoposide given by this schedule is unlikely to be of any value in refractory myeloma.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Dosage Regimen: Multiple Oral Dosage
Subviral Agents

